LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Intellectual property in entomology: Analysis and perspective on recent trends in global patent publications.

    Hamm, Ronda L / Gregg, Anne / Sparks, Thomas C

    Pest management science

    2020  Volume 76, Issue 5, Page(s) 1603–1611

    Abstract: Intellectual property (IP) is an important consideration for entomological research and provides a means to capture value from new discoveries. Herein, we describe an analysis of more than 26 000 patent publications from 2007-2017 related to the field of ...

    Abstract Intellectual property (IP) is an important consideration for entomological research and provides a means to capture value from new discoveries. Herein, we describe an analysis of more than 26 000 patent publications from 2007-2017 related to the field of entomology. These patents were divided among 8000 patent assignees; however, only 5% of the assignees had ≥10 patents. Corporations accounted for the largest share of patents (59%), with individuals (20%), academic institutions (17%) and government organizations (4%) making up the remaining segments. From 2007-2017 the number of entomological patents increased by 400%, with the largest number being from China. However, unlike patents from Europe, Japan or the US, which target a range of countries, the Chinese patents almost exclusively focus on China. Among the array of subjects covered are transgenic insects and plants, repellents, recombinant insect cells, with the highest proportion of patents focused on insecticides (39%), followed by insecticide mixtures (27%) and formulations (21%). The top 30 patent assignees included companies/institutions from China (18), Europe (3), Japan (6) and the US (3). Among the top 12 entities, IP from the US assignees was distributed across insecticides, mixtures and insecticidal traits while those from China were more focused on mixtures. However, given expanding IP numbers from China it is expected that in the future there will be a greater impact on new insecticides and related technologies. © 2020 Society of Chemical Industry.
    MeSH term(s) China ; Europe ; Humans ; Intellectual Property ; Japan ; Publications
    Language English
    Publishing date 2020-02-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001705-4
    ISSN 1526-4998 ; 1526-498X
    ISSN (online) 1526-4998
    ISSN 1526-498X
    DOI 10.1002/ps.5780
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Open transcatheter valve implantation for mitral annular calcification: One-year outcomes.

    Hamid, Umar Imran / Gregg, Anne / Ball, Peter / Owens, Colum / Manoharan, Ganesh / Spence, Mark S / Jeganathan, Reuben

    JTCVS techniques

    2021  Volume 10, Page(s) 254–261

    Abstract: Background: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to ...

    Abstract Background: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI with severe mitral annular calcification and their procedural outcomes.
    Methods: Retrospective analysis of patients from 2017 to 2020 referred for TMVI was carried out. Demographic characteristic details; surgical strategy; perioperative complications; and hospital stay, including 30-day and 1-year mortality, were analyzed.
    Results: Eleven patients were referred for consideration of TMVI. The 8 patients who underwent TMVI had a median age of 74 years (range, 57-80 years), the median Society of Thoracic Surgeons score was 4.6 (range, 2.4-10.9), and European System for Cardiac Operative Risk Evaluation II score was 5.2% (2%-10.1%). The median cardiopulmonary bypass time and crossclamp times were 170 minutes (range, 150-248 minutes) and 152 minutes (range, 118-214 minutes), respectively. The median hospital stay was 29 days (range, 2-40 days). Thirty-day in hospital mortality was 12%, whereas 1-year mortality was 25%. There was symptomatic improvement with downgrade of New York Heart Association functional class from III or IV to I or II. The 3 patients who were turned down had a median age of 73 years, median Society of Thoracic Surgeons score was 13.4, and median European System for Cardiac Operative Risk Evaluation II score was 5.72%. They were alive at 12 months follow-up from the date of surgical assessment; however, all with New York Heart Association functional class III or IV symptoms.
    Conclusions: We describe a series demonstrating the technical consideration and capability of transatrial TMVI to treat mitral annular calcification and native mitral valve disease. Our results are favorable when compared with TMVI global registry data for transseptal or transapical approach.
    Language English
    Publishing date 2021-08-10
    Publishing country United States
    Document type Journal Article
    ISSN 2666-2507
    ISSN (online) 2666-2507
    DOI 10.1016/j.xjtc.2021.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Assay Techniques and Test Development for COVID-19 Diagnosis.

    Carter, Linda J / Garner, Linda V / Smoot, Jeffrey W / Li, Yingzhu / Zhou, Qiongqiong / Saveson, Catherine J / Sasso, Janet M / Gregg, Anne C / Soares, Divya J / Beskid, Tiffany R / Jervey, Susan R / Liu, Cynthia

    ACS central science

    2020  Volume 6, Issue 5, Page(s) 591–605

    Keywords covid19
    Language English
    Publishing date 2020-04-30
    Publishing country United States
    Document type News
    ISSN 2374-7943
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00501
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V / Watkins, Steve P / Carter, Linda J / Smoot, Jeffrey / Gregg, Anne C / Daniels, Angela D / Jervey, Susan / Albaiu, Dana

    ACS central science

    2020  Volume 6, Issue 3, Page(s) 315–331

    Keywords covid19
    Language English
    Publishing date 2020-03-12
    Publishing country United States
    Document type News
    ISSN 2374-7943
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00272
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: A review of physiological and behavioral changes during pregnancy and lactation: potential exposure factors and data gaps.

    Moya, Jacqueline / Phillips, Linda / Sanford, Jessica / Wooton, Maureen / Gregg, Anne / Schuda, Laurie

    Journal of exposure science & environmental epidemiology

    2014  Volume 24, Issue 5, Page(s) 449–458

    Abstract: Exposures to environmental contaminants can pose risks to pregnant women's health, their developing fetuses, children, and adults later in their lives. Assessing risks to this potentially susceptible population requires a sound understanding of the ... ...

    Abstract Exposures to environmental contaminants can pose risks to pregnant women's health, their developing fetuses, children, and adults later in their lives. Assessing risks to this potentially susceptible population requires a sound understanding of the physiological and behavioral changes that occur during pregnancy and lactation. Many physiological and anatomical changes occur in a woman's organ systems during the course of pregnancy and lactation. For example, blood volume and cardiac output increase during pregnancy, and other metabolic functions are altered to provide for the demands of the fetus. During lactation, nutritional demands are greater than during pregnancy. There are also changes in behavior during both pregnancy and lactation. For example, water consumption during pregnancy and lactation increases. These behavioral and physiological changes can lead to different environmental exposures than these women might otherwise experience in the absence of pregnancy or lactation. This paper provides a summary of information from the published literature related to behavioral and physiological changes in pregnant and lactating women that may affect their exposure or susceptibility to environmental contaminants, provides potentially useful exposure factor data for this population of women, and highlights data gaps.
    MeSH term(s) Adolescent ; Adult ; Behavior ; Environmental Exposure ; Female ; Humans ; Lactation/physiology ; Pregnancy/physiology ; Young Adult
    Language English
    Publishing date 2014-01-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2218551-3
    ISSN 1559-064X ; 1559-0631
    ISSN (online) 1559-064X
    ISSN 1559-0631
    DOI 10.1038/jes.2013.92
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Assay Techniques and Test Development for COVID-19 Diagnosis

    Carter, Linda J. / Garner, Linda V. / Smoot, Jeffrey W. / Li, Yingzhu / Zhou, Qiongqiong / Saveson, Catherine J. / Sasso, Janet M. / Gregg, Anne C. / Soares, Divya J. / Beskid, Tiffany R. / Jervey, Susan R. / Liu, Cynthia

    ACS Cent. Sci.

    Abstract: An ongoing theme of the COVID-19 pandemic is the need for widespread availability of accurate and efficient diagnostic testing for detection of SARS-CoV-2 and antiviral antibodies in infected individuals. This report describes various assay techniques and ... ...

    Abstract An ongoing theme of the COVID-19 pandemic is the need for widespread availability of accurate and efficient diagnostic testing for detection of SARS-CoV-2 and antiviral antibodies in infected individuals. This report describes various assay techniques and tests for COVID-19 diagnosis. Most tests for early detection of SARS-CoV-2 RNA rely on the reverse transcription-polymerase chain reaction, but isothermal nucleic acid amplification assays, including transcription-mediated amplification and CRISPR-based methodologies, are promising alternatives. Identification of individuals who have developed antibodies to the SARS-CoV-2 virus requires serological tests, including enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay. This report also provides an overview of current development in COVID-19 diagnostic techniques and products to facilitate future improvement and innovation.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #142071
    Database COVID19

    Kategorien

  7. Article: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V. / Watkins, Steve P. / Carter, Linda J. / Smoot, Jeffrey / Gregg, Anne C. / Daniels, Angela D. / Jervey, Susan / Albaiu, Dana

    ACS Cent. Sci.

    Abstract: Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this ... ...

    Abstract Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV. The patent analysis of coronavirusrelated biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #8271
    Database COVID19

    Kategorien

  8. Article ; Online: Assay Techniques and Test Development for COVID-19 Diagnosis

    Carter, Linda J. / Garner, Linda V. / Smoot, Jeffrey W. / Li, Yingzhu / Zhou, Qiongqiong / Saveson, Catherine J. / Sasso, Janet M. / Gregg, Anne C. / Soares, Divya J. / Beskid, Tiffany R. / Jervey, Susan R. / Liu, Cynthia

    ACS Central Science

    2020  Volume 6, Issue 5, Page(s) 591–605

    Keywords covid19
    Language English
    Publisher American Chemical Society (ACS)
    Publishing country us
    Document type Article ; Online
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00501
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

    Liu, Cynthia / Zhou, Qiongqiong / Li, Yingzhu / Garner, Linda V. / Watkins, Steve P. / Carter, Linda J. / Smoot, Jeffrey / Gregg, Anne C. / Daniels, Angela D. / Jervey, Susan / Albaiu, Dana

    ACS Central Science

    2020  Volume 6, Issue 3, Page(s) 315–331

    Keywords covid19
    Language English
    Publisher American Chemical Society (ACS)
    Publishing country us
    Document type Article ; Online
    ISSN 2374-7943
    DOI 10.1021/acscentsci.0c00272
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

    Biedenbender, Rex / Bevilacqua, Joan / Gregg, Anne M / Watson, Mike / Dayan, Gustavo

    The Journal of infectious diseases

    2010  Volume 203, Issue 1, Page(s) 75–84

    Abstract: Background: ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus. This Phase II, randomized, double-blind, placebo-controlled, multicenter study assessed the immunogenicity, viremia, and safety of the ChimeriVax- ... ...

    Abstract Background: ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus. This Phase II, randomized, double-blind, placebo-controlled, multicenter study assessed the immunogenicity, viremia, and safety of the ChimeriVax-WN02 vaccine.
    Methods: The 2-part study included adults in general good health. In part 1, subjects aged 18-40 years were randomized to 1 of 4 treatment groups: ChimeriVax-WN02 3.7- × -10(5) plaque-forming units (PFU), 3.7 × 10(4) PFU, 3.7 × 10(3) PFU, or placebo. In part 2, subjects aged 41-64 and ≥ 65 years were randomized to receive ChimeriVax-WN02 3.7 × 10(5) PFU or placebo.
    Results: In both part 1 and part 2, seroconversion was achieved at day 28 by >96% of subjects in active treatment groups. In part 1, neutralizing antibody titers at day 28 were higher and viremia levels lower with the highest dose, whereas the adverse event profile was similar between the dose groups. In part 2, antibody titers and viremia levels were higher in subjects aged ≥ 65 years, and more subjects in the 41-64 years cohort experienced adverse events.
    Conclusions: The ChimeriVax-WN02 vaccine was highly immunogenic in younger adults and the elderly, and it was well tolerated at all dose levels and in all age groups investigated. Clinical Trials.gov identifier: NCT00442169.
    MeSH term(s) Adolescent ; Adult ; Aged ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Double-Blind Method ; Female ; Human Experimentation ; Humans ; Male ; Middle Aged ; Placebos/administration & dosage ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/immunology ; Viremia ; West Nile Virus Vaccines/adverse effects ; West Nile Virus Vaccines/immunology ; Young Adult
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; ChimeriVax ; Placebos ; Vaccines, Attenuated ; West Nile Virus Vaccines
    Language English
    Publishing date 2010-12-09
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiq003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top